CTNNB1 and hemoglobin measurement: Hepatoblastoma (HB) is the main pediatric liver cancer; however, it is a very rare disease with an approximate incidence of one case in 1 million children per year.1 HB is characterized by a low mutation burden,2 but with a high recurrence of activating CTNNB1 mutations3,4; hence, the determinants of the clinical heterogeneity of HB are mainly related to differences in their transcriptome and epigenome rather than its genome.